Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease clinically defined as the combined degeneration of corticospinal and corticobulbar neurons (CSN), and bulbar and spinal motor neurons (MN). A growing body of evidence points to the motor cortex, where CSN are located, as the potential initiation site of ALS. However, little is known about the spatiotemporal dynamics of CSN degeneration and the molecular pathways involved. Here, we show in the Sod1 G86R mouse model of ALS that CSN loss precedes MN degeneration and that CSN and MN degenerations are somatotopically related, highlighting the relevance of CSN to ALS onset and progression. To gain insights into the molecular mechanisms that selectively trigger CSN degeneration, we purified CSN from the motor and somatosensory cortex of adult mice and analysed their transcriptome from presymptomatic ages to disease end-stage. Significant RNA metabolism and splicing alterations, novel in the context of Sod1 mutation, were identified, including mis-splicing events that largely trigger genes involved in neuronal functions. Together, the data indicate that CSN dysfunction and degeneration upon mutant Sod1 expression involve alterations of RNA metabolism and splicing, emphasizing shared mechanisms across various ALS-related genes.3 ALS is an incurable and fatal neurodegenerative disease that mostly starts in adulthood with a rapidly progressing paralysis and death within only 2 to 5 years of diagnosis 1,2 . In clinics, ALS is defined as the combined degeneration of both corticospinal and corticobulbar neurons (CSN, or upper motor neurons) whose cell bodies are located in the cerebral cortex and that extend axons to the medulla and spinal cord, and of spinal and bulbar motor neurons (MN, or lower motor neurons) whose cell bodies are located in the medulla and spinal cord, and that connect to the skeletal muscles. If the cellular and molecular mechanisms behind MN degeneration are relatively well known, the numerous related clinical trials have unfortunately failed to translate into improved treatment of ALS 1-4 , a discrepancy that contributed to the emergence of the CSN and the overall cerebral cortex as alternative therapeutic targets.A growing body of evidence points to the motor cortex as the likely initiation site of ALS 5,6 . A first series of arguments arose from the recent genetic, pathological and clinical evolution links established between ALS and FrontoTemporal Dementia (FTD), a neurodegenerative disease that affects solely the cerebral cortex and results in behavioural and cognitive deficits 7 . A second series of arguments emerged following extensive examination of the TDP-43 aggregates, a pathological hallmark of the disease in post-mortem brains from ALS patients, identifying the motor cortex as the most affected region of the brain, and leading to the corticofugal hypothesis 8-10 which proposes a sequential pattern of pathology spreading from the motor cortex to its projection sites. Finally, transcranial magnetic stimulation studi...